Bedaquiline, Delamanid, Linezolid, and Clofazimine for Treatment of Pre-extensively Drug-Resistant Tuberculosis

BACKGROUND: Treatment success rates for multidrug-resistant tuberculosis (MDR-TB) remain low globally. Availability of newer drugs has given scope to develop regimens that can be patient-friendly, less toxic, with improved outcomes. We proposed to determine the effectiveness of an entirely oral, sho...

Descripción completa

Detalles Bibliográficos
Autores principales: Padmapriyadarsini, Chandrasekaran, Vohra, Vikram, Bhatnagar, Anuj, Solanki, Rajesh, Sridhar, Rathinam, Anande, Lalitkumar, Muthuvijaylakshmi, M, Rana, Meera Bhatia, Jeyadeepa, Bharathi, Taneja, Gaurav, Balaji, S, Shah, Prashant, Saravanan, N, Chavan, Vijay, Kumar, Hemanth, Ponnuraja, Chinnayin, Livchits, Viktoriya, Bahl, Monica, Alavadi, Umesh, Sachdeva, K S, Swaminathan, Soumya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907500/
https://www.ncbi.nlm.nih.gov/pubmed/35767251
http://dx.doi.org/10.1093/cid/ciac528

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907500/
https://www.ncbi.nlm.nih.gov/pubmed/35767251
http://dx.doi.org/10.1093/cid/ciac528

Ejemplares similares